NCT02888743 2026-03-18
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
763 trialsNCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03896503 2026-03-18
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04484142 2026-03-17
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
Phase 2 Completed
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT03523702 2026-03-10
SPRINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT02642042 2026-03-04
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03057106 2026-03-03
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03083041 2026-03-03
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03940703 2026-02-27
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono
Phase 2 Active not recruiting
NCT04606771 2026-02-27
CoC
AstraZeneca
Phase 2 Active not recruiting
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT02513563 2026-02-19
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04515004 2026-02-17
Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
VA Office of Research and Development
Phase 2 Terminated
NCT05775289 2026-02-11
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03778229 2026-02-10
SAVANNAH
AstraZeneca
Phase 2 Active not recruiting
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05577702 2026-02-09
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Completed
NCT03133546 2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04619004 2026-01-23
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Active not recruiting
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03563716 2026-01-20
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT04452877 2026-01-13
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
Phase 2 Completed
NCT02442349 2026-01-09
AURA17
AstraZeneca
Phase 2 Completed
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06029127 2026-01-05
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Completed
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT02864992 2025-12-23
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
EMD Serono
Phase 2 Active not recruiting
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02314364 2025-12-16
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Massachusetts General Hospital
Phase 2 Completed
NCT05001347 2025-12-16
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Phase 2 Completed
NCT03836066 2025-12-04
TELMA
Fundación GECP
Phase 2 Completed
NCT02259621 2025-12-03
NA_00092076
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03132532 2025-11-25
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT04644237 2025-11-21
DESTINY-LUNG02
Daiichi Sankyo
Phase 2 Completed
NCT01847209 2025-11-18
Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions
Brigham and Women's Hospital
Phase 2 Completed
NCT03915951 2025-11-17
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT04396535 2025-11-17
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT02823990 2025-11-10
TG4010 and Nivolumab in Patients With Lung Cancer
University of California, Davis
Phase 2 Completed
NCT02316002 2025-11-06
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03909971 2025-11-05
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Pfizer
Phase 2 Completed